Please assess the completion status of the following clinical trial:

Trial Title: Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. One or more episodes recurrent CDI (defined as \> 3 loose/watery stools/24h for 2 consecutive days with CDI treatment, and not explained by another diagnosis plus laboratory confirmation of C. difficile; or ileus, or toxic megacolon plus laboratory confirmation of C. difficile, occurring within 90 days of a prior CDI episode with similar symptoms and laboratory confirmation)~2. Resolution or improvement of symptoms from most recent CDI episode, defined as no longer meeting the clinical definition for CDI for a 48 hour period during treatment, including not meeting the definition again after an initial improvement~3. Within the enrollment window: 2 days after completion of antimicrobial therapy for CDI (to allow for a washout period) to 14 days after completion of therapy or 30 days after the onset of CDI whichever is later.~4. Age 18 years~5. Enrolled in a Veterans Health Administration (VHA) facility~6. Able and willing to provide informed consent~Exclusion Criteria:~1. Unlikely to swallow capsules~2. Pregnancy, planning to be pregnant, or breastfeeding~3. Receipt of cytotoxic chemotherapy, intravenous or subcutaneous immune globulin, or confirmed neutropenia (absolute neutrophil count of \< 1,000 cells/ L) within the past 3 months~4. Inflammatory bowel disease or other chronic diarrheal disease/fecal incontinence predating CDI~5. Ongoing antibiotic use other than those for the current episode of CDI~6. Prior FMT~7. Life expectancy of \< 8 weeks~8. Anaphylactic food allergy~9. Active enrollment in another research study on antibiotics, probiotics, or FMT without investigators approval~10. Presence of an ileostomy or colostomy~11. HIV with Clusters of Differentiation 4 (CD4) cell count \< 200 cells/µL in prior 3 months~12. Decompensated cirrhosis~13. Bone marrow/peripheral blood stem cell transplant in the past year~14. Unlikely to follow study protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Fecal Microbiota Therapy (FMT)
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).